PharmaShots | Incisive News in 3 Shots

Subscribe Now

Respiratory Complications

AstraZenca's Calquence (acalabrutinib) Fails to Meet its Primary Endpoint in P-II Studies for COVID-19

AstraZenca's Calquence (acalabrutinib) Fails to Meet its Primary Endpoint in P-II Studies for COVID-19

November 12, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us